Pharmaron Acquires Majority Stake in Biortus Biosciences

Reuters10-29

Pharmaron Acquires Majority Stake in Biortus Biosciences

Pharmaron Beijing Co., Limited has entered into a definitive agreement to acquire an 82.54% equity interest in Biortus Biosciences Co., Ltd. and its affiliates. The deal is expected to significantly enhance Pharmaron's technological platform and service capabilities in structural biology, complex protein production and analysis, and structure-based drug discovery. Biortus brings expertise in protein science, biological assaying, protein crystallization, and AI/ML-based computational platforms for protein complex design and structure analysis. The acquisition is set to strengthen Pharmaron's integrated, multi-modality services platform and expand its ability to serve global biopharmaceutical clients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmaron Beijing Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251028810538) on October 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579614149?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579614149","market":"fut","top_or_hot":-1,"title":"Pharmaron Acquires Majority Stake in Biortus Biosciences","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharmaron Acquires Majority Stake in Biortus Biosciences\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PHBBF\">Pharmaron Beijing</a> Co., Limited has entered into a definitive agreement to acquire an 82.54% equity interest in Biortus Biosciences Co., Ltd. and its affiliates. The deal is expected to significantly enhance Pharmaron's technological platform and service capabilities in structural biology, complex protein production and analysis, and structure-based drug discovery. Biortus brings expertise in protein science, biological assaying, protein crystallization, and AI/ML-based computational platforms for protein complex design and structure analysis. The acquisition is set to strengthen Pharmaron's integrated, multi-modality services platform and expand its ability to serve global biopharmaceutical clients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/300759\">Pharmaron Beijing</a> Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251028810538) on October 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron Acquires Majority Stake in Biortus Biosciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron Acquires Majority Stake in Biortus Biosciences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-29 00:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharmaron Acquires Majority Stake in Biortus Biosciences\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PHBBF\">Pharmaron Beijing</a> Co., Limited has entered into a definitive agreement to acquire an 82.54% equity interest in Biortus Biosciences Co., Ltd. and its affiliates. The deal is expected to significantly enhance Pharmaron's technological platform and service capabilities in structural biology, complex protein production and analysis, and structure-based drug discovery. Biortus brings expertise in protein science, biological assaying, protein crystallization, and AI/ML-based computational platforms for protein complex design and structure analysis. The acquisition is set to strengthen Pharmaron's integrated, multi-modality services platform and expand its ability to serve global biopharmaceutical clients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/300759\">Pharmaron Beijing</a> Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251028810538) on October 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300759","symbol_name":"康龙化成","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL4dNSTy:1","article_id":"2579614149","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579614149","pubTimestamp":1761667227,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pharmaron Beijing Co., Limited has entered into a definitive agreement to acquire an 82.54% equity interest in Biortus Biosciences Co., Ltd. and its affiliates. The deal is expected to significantly enhance Pharmaron's technological platform and service capabilities in structural biology, complex protein production and analysis, and structure-based drug discovery. Biortus brings expertise in protein science, biological assaying, protein crystallization, and AI/ML-based computational platforms for protein complex design and structure analysis. The acquisition is set to strengthen Pharmaron's integrated, multi-modality services platform and expand its ability to serve global biopharmaceutical clients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or leg","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300759":"康龙化成","BK0216":"研究试验"},"translate_title":"康龙化成收购Biortus Biosciences多数股权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300759":0.9},"content_text":"Pharmaron Acquires Majority Stake in Biortus Biosciences\n    \n\nPharmaron Beijing Co., Limited has entered into a definitive agreement to acquire an 82.54% equity interest in Biortus Biosciences Co., Ltd. and its affiliates. The deal is expected to significantly enhance Pharmaron's technological platform and service capabilities in structural biology, complex protein production and analysis, and structure-based drug discovery. Biortus brings expertise in protein science, biological assaying, protein crystallization, and AI/ML-based computational platforms for protein complex design and structure analysis. The acquisition is set to strengthen Pharmaron's integrated, multi-modality services platform and expand its ability to serve global biopharmaceutical clients.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmaron Beijing Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251028810538) on October 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579614149","isCrawlerRequest":true}